Beyond the lab: vaccine development
This report provides insights into current research and future prospects from potential breakthroughs to global collaboration in pandemic preparedness.
List view / Grid view
This report provides insights into current research and future prospects from potential breakthroughs to global collaboration in pandemic preparedness.
The proof-of-concept study could lead to a cure for HIV that inactivates diverse strains across multiple cellular contexts.
Researchers have created a nanomedicine loaded with siRNAs, which demonstrated a 73 percent reduction in HIV replication.
Researchers discover a mechanism that could be exploited for targeting other viruses that build capsids to hide from host defences.
The discovery that HIV capsids are importin-like transporters could be exploited for improved AIDS therapies.
The new findings could help preventive and therapeutic HIV vaccine design and development, and HIV immunotherapy approaches.
New Salk Institute, US, research could lead to the development of new HIV therapeutics that overcome resistance to existing drugs.
In this article, Drug Target Review’s Izzy Wood and Ria Kakkad share some of the most ground-breaking moments from drug discovery this year.
An experimental HIV vaccine, delivered as increasing doses over several days, led to long-lasting and diverse antibody production in monkeys.
Researchers in the US have developed a potential HIV vaccine approach that aims to prompt the creation of broadly neutralising antibodies via mRNA.
A new computer-based approach could help clinicians select the best combinations of broadly neutralising antibodies to treat HIV based on the virus’ genetics, while minimising the risk of the virus escaping treatment.
Researchers have discovered how immune system dendritic cells are key to maintaining and regulating response to immunotherapy.
Scientists at Northwestern Medicine have developed new techniques in human blood to pave potential paths towards a HIV cure.
A recent study has shown that antiretroviral therapy timing impacts the animal version of HIV and latent tuberculosis.
A new potential mRNA vaccine that delivers instructions for making two key HIV proteins has been tested in mice and rhesus macaques.